Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects - Reilly, P A; van Ryn, J; Grottke, O; Glund, S; Stangier, J (Am J Med, 2016)
(11S):